Enough stockpile of vaccines for priority groups in first phase: VK Paul
India has enough stockpile of the Covid-19 vaccine for inoculation of priority groups, including healthcare workers and frontline workers, in the first phase, Niti Aayog member VK Paul said on Monday.
Paul, who is also the Chairman of National Expert Group On Vaccine Administration for Covid-19 (NEGVAC) further said the government will soon announce its plans for purchase and distribution of Covid-19 vaccine.
“Our first phase (of vaccination) comprises priority groups with high risk of mortality and our healthcare and frontline workers. For them, we believe, we have enough (Covid-19 vaccine) stockpile,” he told PTI in an interview.
India’s drug regulator DCGI on Sunday approved the Oxford Covid-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, paving the way for a massive inoculation drive.
Paul noted that “three to four months from now, there will be other vaccines and the stockpile will be even bigger. “And more acceleration can be brought about in the vaccination programme,” Paul added.
Asked when the government will announce its plans for purchase and distribution of Covid-19 vaccine, he said, “this will follow. Now the essential has taken place, all these steps will be taken.” Asked what would be the single biggest challenge in mass vaccination for Covid-19, Paul noted that the biggest challenge encompasses the huge mobilisation that is required for such an effort.
“Well, the single most important challenge for mass vaccination on such a scale is mobilising beneficiaries on the appointed day and to conduct sessions in smooth, systemic protocols, ensuring Covid-19 appropriate precautions, I think is the single biggest challenge,” he observed.
According to Paul, the purpose of vaccination is a staggered ambition and can be seen as hierarchical.
“Ultimately, we would like vaccination to stop, stall and extinguish the pandemic, that is the ultimate purpose,” he said adding that for that to be achieved, a herd immunity of about 70% has to be created either through vaccination or by adding those people who have undergone natural infection.
Paul pointed out that for normal life to go on, there should be enough vaccinated people, so that the country’s industry, schools, transportation, judicial system and Parliamentary activity go on.
“Even though the virus may be there, the pandemic may not have finished but enough of economic and social life could go on,” he emphasised.
Replying to a question that India does not have experience in adult vaccination, the Niti Aayog member noted that countries face new challenges and then they respond on the basis of their intrinsic capability.
“We have tremendous experience of running immunisation programs. We have experience of running affairs like national elections which happen over a short period of time across the country,” he said.
“So those experiences and those SOP will come handy and build on that India’s ingenuity, India’s innovation and India’s experience will make it possible for us to mount a successful vaccination programme, even though it is unprecedented,” he added.
Referring to the health ministry’s recently issued ‘Covid-19 Vaccine Operational Guidelines’, Paul said, “God forbid, if you have any comorbidity, then you will get a vaccine in the first phase of the vaccination programme. Otherwise, you will get after these high priority groups have been covered.”
India’s drug regulator DCGI on Sunday approved the Oxford Covid-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country.
The approval by the Drugs Controller General of India (DCGI) was given on the basis of recommendations submitted by a Covid-19 subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).
“After adequate examination, CDSCO has decided to accept the recommendations of the Expert Committee and accordingly, vaccines of M/s Serum and M/s Bharat Biotech are being approved for restricted use in emergency situations,” DCGI Dr VG Somani had said.
This paves the way for the rollout of at least two vaccines in India in the coming days.
The Serum Institute of India, the world’s largest vaccine manufacturer, has tied up with AstraZeneca to manufacture Covishield.
Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
Also, the authority granted Cadila Healthcare the permission to conduct the Phase III clinical trial of its vaccine candidate in India, Somani had said.
Enter your email to get our daily newsletter in your inbox
- For 2020-21, Delhi had pegged budgeted revenue receipts (excluding borrowings) at ₹55,309 crore. Revised estimates for the year will be mentioned in the upcoming budget (2021-22) and actual revenue receipts for the year will reflect in the budget after that.
- Court-appointed amicus curiae senior advocate Siddhartha Dave prepared a chart indicating unsatisfactory response from states as well with some proposing to achieve compliance of Court’s December 2, 2020 order by end of 2023.
- The judgment, which involved approximately ₹500 crore in tax revenue, will impact companies such as IBM India Ltd, Samsung Electronics Co Ltd, Hewlett Packard India, Mphasis Ltd, Sonata Software Ltd, and GE India, among others.
- The girl's family lodged a complaint three day after she went missing.
- Shubhendu Shubham, 23, a 2016-batch student of Patna’s Nalanda Medical College Hospital (NMCH), had taken the first shot of Covaxin in the first week of February, but tested positive for the viral infection later last month before he could take the second shot
- For the past 13 days, the Durga-Nag market at Dalgate in Srinagar has been desolate and locals and traders in grief
- TMC’s leader in the Rajya Sabha Derek O, Brien asked the Election Commission to stop the Prime Minister "from taking unfair advantages and undue publicity at tax payer’s cost during the conduct of elections".